Quanterix Corporation (QTRX) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Quanterix Corporation (NASDAQ: QTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $3.15 (+0.80% 1D, market cap $148.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTRX ranks #967 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), QTRX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 46.8%, and ROIC of -35.0%. By comparison, SEER (Seer Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -29.1%, cap $107.4M) and LAB (Standard BioTools Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M). Among the 5-stock peer group, QTRX leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).
Per QTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503274), Quanterix Corporation generated $138.9M in revenue (+1.1% YoY), -$107.2M in net income, and -$79.8M in free cash flow against $418.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While QTRX currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.99) and Max Pain ($3.31) forces dealer call-delta covering toward $9.21.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Quanterix Corporation (QTRX) advanced +0.80% to $3.15, trading at 15% of its 52-week range ($2.15 – $8.77). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BILLERICA, Mass., October 28, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QTRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QTRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Quanterix Corporation (QTRX) ranks #967 by composite RQD confidence (23/100, grade E) and #612 by equity capitalization ($148.7M). Within this direct 5-issuer industry benchmark cohort, QTRX leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTRX at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QTRX
ACTIVE
Quanterix Corporation | E | 23/100 | — | 46.8% | -35.0% | +0.80% | $148.7M | Benchmark Subject |
| SEER Seer Inc. (Class A) | D- | 36/100 | — | 51.1% | -29.1% | -2.51% | $107.4M | /seer-vs-qtrx → |
| LAB Standard BioTools Inc. | E | 27/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | /lab-vs-qtrx → |
| NAUT Nautilus Biotechnology Inc. | D- | 43/100 | — | — | -35.0% | -2.18% | $399.9M | /naut-vs-qtrx → |
| HBIO Harvard Bioscience Inc. | D | 47/100 | — | 57.7% | -35.0% | +4.51% | $40.1M | /hbio-vs-qtrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quanterix Corporation (QTRX) reported GAAP revenue of $138.9M (+1.1% vs. FY2024 revenue of $137.4M , and +13.5% cumulative change since FY2023) , GAAP net income of -$107.2M, operating cash flow of -$77.2M, and free cash flow of -$79.8M (-107.2% YoY). On the balance sheet, QTRX closed FY2025 with $418.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $138.9M | -$107.2M | -$77.2M | -$79.8M | $418.8M | — |
| FY2024 (FY) | 2024-12-31 | $137.4M | -$38.5M | -$35.2M | -$38.5M | $406.5M | — |
| FY2023 (FY) | 2023-12-31 | $122.4M | -$28.4M | -$18.8M | -$18.8M | — | — |
As of 2026-11-02, Quanterix Corporation (NASDAQ: QTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $3.15 (+0.80% 1D, market cap $148.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTRX ranks #967 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), QTRX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 46.8%, and ROIC of -35.0%. By comparison, SEER (Seer Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -29.1%, cap $107.4M) and LAB (Standard BioTools Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M). Among the 5-stock peer group, QTRX leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).
Per QTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503274), Quanterix Corporation generated $138.9M in revenue (+1.1% YoY), -$107.2M in net income, and -$79.8M in free cash flow against $418.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
QTRX last traded at $3.15 (+0.80% on volume of 334,197 shares), positioning the stock +5.35% above its 50-day simple moving average ($2.99) and -17.97% below its 200-day simple moving average ($3.84). Across its 52-week range of $2.15 to $8.77, QTRX sits at the 15.1% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.76 to $3.54).
Why QTRX Stock advanced +0.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).